Jay S. Loeffler
Molecular Biology · 2000–2010
A researcher in the Science corpus: 6 papers; trusts 4 researchers and is trusted by 1 researcher here, as inferred from the citation graph.
Subfields
- Molecular Biology — 62 citations into it; #12,727 of 17,773 by trust here, #5,968 by citations
- Cancer Research — 37 citations into it; #1,557 of 1,780 by trust here, #889 by citations
- Oncology — 37 citations into it; #1,311 of 1,698 by trust here, #1,204 by citations
- Pulmonary and Respiratory Medicine — 9 citations into it
- Radiology, Nuclear Medicine and Imaging — 8 citations into it
Whom Jay S. Loeffler trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
Who trusts Jay S. Loeffler overall
Papers from Jay S. Loeffler's perspective
Ordered by how strongly the researchers Jay S. Loeffler trusts endorse each paper. Same corpus, a different order for every researcher.
- Dissecting tumour pathophysiology using intravital microscopy (Nature Reviews. Cancer)
- Tumor Response to Radiotherapy Regulated by Endothelial Cell Apoptosis (Science)
- Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy (Nature Medicine)
- Angiogenesis in life, disease and medicine (Nature)
- Pathology: Cancer cells compress intratumour vessels (Nature)
- Pathophysiological consequences of VEGF-induced vascular permeability (Nature)
- Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy? (Nature Reviews. Cancer)
- Repopulation of cancer cells during therapy: an important cause of treatment failure (Nature Reviews. Cancer)
- Vascular Normalization by Vascular Endothelial Growth Factor Receptor 2 Blockade Induces a Pressure Gradient Across the Vasculature and Improves Drug Penetration in Tumors (Cancer Research)
- BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis (Cancer Research)
Their papers
- AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. (2007) — 1,814 citations
- Lessons from phase III clinical trials on anti-VEGF therapy for cancer (2006) — 1,099 citations
- Angiogenesis in brain tumours (2007) — 1,441 citations
- Charged particles in radiation oncology (2010) — 713 citations
- Relative biological effectiveness (RBE) values for proton beam therapy. (2002) — 1,317 citations
- Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases: final report of RTOG protocol 90-05. (2000) — 1,548 citations